Renvatinib mesylate preparation and application thereof

By designing a two-particle preparation of lanvatinib methanesulfonate and saccorin in different pH environments, the problem of decomposition of lanvatinib methanesulfonate under wet and heat conditions is solved, and its stability and therapeutic effect are improved. A synergistic effect in anti-tumor treatment was achieved.

CN118976037APending Publication Date: 2024-11-19ZIBO CENT HOSPITAL
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411052286.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing lanvatinib methanesulfonate preparations are easily decomposed under wet and heat storage conditions, and their stability and therapeutic effects are limited, making it difficult to maintain drug activity in different pH environments.

Method used

Using a two-grain drug preparation design, lanvatinib methanesulfonate is mixed with sodium bicarbonate in a weak alkaline environment, and pelletizes the sacrinoside and L-lactic acid are mixed in a weak acid environment, and are pelleted by dextrin and The combination of ethanol forms a dry, tight tablet to ensure that the drug is stable under appropriate pH conditions.

Benefits of technology

It significantly improves the stability of lenvatinib methanesulfonate and saccordingol, ensures the effectiveness and therapeutic effect of the drug under different pH environments, and expands its indication range in anti-tumor treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976037A_ABST
    Figure CN118976037A_ABST
Patent Text Reader

Abstract

The invention relates to a lenvatinib mesylate preparation and application thereof, and belongs to the technical field of antitumor drugs. The lenvatinib mesylate preparation is prepared from lenvatinib mesylate, rhoifolin, dextrin, sodium bicarbonate, L-lactic acid, a filling agent, a disintegrating agent, a lubricating agent and a wetting agent. According to the present invention, the drug combination of the lenvatinib mesylate and the rhoifolin is utilized to provide the significant synergistic effect in the anti-tumor aspect, and the lenvatinib mesylate and the rhoifolin are respectively coated in the weakly alkaline environment and the weakly acidic environment so as to jointly maintain the stability of the two active components;
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of anti-tumor drugs, and in particular relates to a lenvatinib mesylate preparation and a use thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Lenvatinib mesylate is a multi-target tyrosine kinase inhibitor that acts on multiple receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGFR), basic fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), tumor angiogenesis-associated protein receptor (RET), etc. It inhibits multiple receptor kinases, affects angiogenesis, cell proliferation and tumor growth, and thus inhibits the progression of cancer. Lenvatinib mesylate is approved for (1) patients with unresectable hepatocellular carcinoma who have not received previous systemic treatment; (2) patients with progressive, locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

[0004] Chinese patent publication number CN101001629A has long disclosed that lenvatinib will decompose under wet and hot storage conditions, and the mesylate salt of lenvatinib also has this defect.

[0005] A Chinese patent with publication number CN116650437A discloses a lenvatinib mesylate capsule and a preparation method thereof, comprising: mixing lenvatinib mesylate, an internal diluent, a disintegrant, a binder and a solvent, and then wet granulating the mixture to obtain wet granules; drying the wet granules to obtain dry granules; mixing the dry granules, an external diluent and a lubricant to obtain intermediate granules of lenvatinib mesylate capsules; the mass percentage of the external diluent in the lenvatinib mesylate capsules is 2 to 8%; and filling the intermediate granules into capsules to obtain the lenvatinib mesylate capsules.

[0006] A Chinese patent with publication number CN117860686A discloses a lenvatinib mesylate composition, which contains lenvatinib mesylate, sodium bentonite, a filler, a binder, and a lubricant, wherein the mass ratio of lenvatinib mesylate, sodium bentonite, the filler, the binder, and the lubricant is (4-20):(10-35):(20-70):(1-20):(0.5-5).

[0007] The Chinese patent with publication number CN115671074A discloses a lenvatinib mesylate preparation and a preparation method thereof, wherein the lenvatinib mesylate preparation comprises the following ingredients: lenvatinib mesylate, calcium carbonate, mannitol, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, microcrystalline cellulose and talc. The C crystal form accounts for 15wt% to 30wt% of the lenvatinib mesylate, and the rest is amorphous. By controlling the content of the C crystal form in the lenvatinib mesylate in the preparation, the preparation has the best dissolution effect, and the batch-to-batch quality difference is also smaller. At the same time, the requirements for the particle size of the raw material lenvatinib mesylate are lower. When the particle size of lenvatinib mesylate is D90≤40μm, a lenvatinib mesylate preparation with uniform particle size distribution, small loading difference and good dissolution effect can be obtained. Summary of the invention

[0008] The invention overcomes the shortcomings of the prior art and provides a lenvatinib mesylate preparation with good efficacy and high stability, which is composed of the following ingredients: 2 to 15 parts by weight of lenvatinib mesylate, 1 to 7 parts by weight of rhubarb glycoside (CAS: 17306-46-6), 30 to 60 parts by weight of dextrin, 2 to 8 parts by weight of sodium bicarbonate, 0.5 to 3 parts by weight of L-lactic acid, 150 to 350 parts by weight of a filler, 4 to 25 parts by weight of a disintegrant, 0.5 to 5 parts by weight of a lubricant, and an appropriate amount of a wetting agent.

[0009] Experiments have found that wild sumac glycoside is more stable in a weakly acidic environment, and its chemical structure and activity may be easier to maintain under conditions where the pH is slightly lower than neutral, while lenvatinib mesylate is more stable in a weakly alkaline environment, and its drug structure and activity may be better protected and maintained under conditions where the pH is slightly higher than neutral. Therefore, ensuring that the drug is in a suitable pH condition can maximize its stability and therapeutic effect, which is crucial for drug formulation design and clinical application. The present invention explores a double-particle drug preparation, in which lenvatinib mesylate is mixed with sodium bicarbonate and granulated in a weakly alkaline environment, and wild sumac glycoside is mixed with L-lactic acid and granulated so that it exists in a weakly acidic environment, and then the two drug-containing granules are tableted to form dry and compact tablets, which can effectively improve the stability of wild sumac glycoside and lenvatinib mesylate.

[0010] Wherein, the wetting agent is water and / or ethanol, preferably an ethanol aqueous solution with a volume fraction of 15-35%.

[0011] Wherein, the filler is selected from at least one of microcrystalline cellulose, mannitol, starch, sucrose and lactose.

[0012] Wherein, the disintegrant is selected from at least one of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, and cross-linked sodium carboxymethyl cellulose.

[0013] Wherein, the lubricant is selected from at least one of magnesium stearate, talcum powder, micro powder silica gel and polyethylene glycol.

[0014] The present invention also provides a method for preparing the above-mentioned lenvatinib mesylate preparation, comprising the following steps:

[0015] (1) micronizing lenvatinib mesylate and rhusin for later use;

[0016] (2) mixing the treated wild sumac glycoside with 1 / 4 to 3 / 4 parts by weight of dextrin and L-lactic acid, adding a wetting agent, wet granulating, drying, and granulating to obtain wild sumac glycoside granules;

[0017] (3) mixing the treated lenvatinib mesylate with the remaining dextrin and sodium bicarbonate, adding a wetting agent, wet granulating, drying, and granulating to obtain lenvatinib mesylate granules;

[0018] (4) Mix the wild sumac glycoside granules with the lenvatinib mesylate granules, add a disintegrant and a lubricant, and press into tablets to obtain the product.

[0019] Dextrin is used as an adhesive and a release agent in the present invention. Dextrin can form a network structure when it meets water. On the one hand, it has a strong thickening effect, and on the other hand, it can isolate two active ingredients. The purpose of adding ethanol is to prevent excessive viscosity, and it is also convenient for drying and avoids the active ingredients from contacting water and decomposing. Therefore, the mixing ratio of ethanol and water is particularly important. After a large number of experiments, it is found that low concentrations of ethanol (volume fraction below 35%, especially 15% to 35%) have the best effect, which can slightly weaken the thickening effect of dextrin, but will not completely destroy its thickening property, and at the same time prevent the active ingredients from excessively contacting water and decomposing.

[0020] To ensure the dissolution effect, the D90 of lenvatinib mesylate and rhusinoside after micronization is 60 μm.

[0021] The present invention also provides the use of the above-mentioned lenvatinib mesylate preparation in the preparation of anti-tumor drugs, and verifies that the combined use of lenvatinib mesylate and rhubarb glycoside can exert a synergistic effect.

[0022] Compared with the prior art, the technical effects of the present invention are:

[0023] (1) The present invention utilizes lenvatinib mesylate in combination with rhusin to exert a significant synergistic effect in anti-tumor effects.

[0024] (2) Since lenvatinib mesylate and rhusin are more stable in different pH environments, the present invention adopts an innovative formulation design to encapsulate lenvatinib mesylate and rhusin in weakly alkaline and weakly acidic environments, respectively, so as to jointly maintain the stability of the two active ingredients. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 : The expression level of HMGB1 in tumor tissues of tumor-bearing rats in each group.

[0026] Figure 2 : The expression level of VEGF in tumor tissues of tumor-bearing rats in each group.

[0027] Figure 3 : Changes in lenvatinib mesylate content during long-term trials of lenvatinib mesylate formulations.

[0028] Figure 4 : Changes of scutellariae glycoside content in long-term trials of lenvatinib mesylate preparations. DETAILED DESCRIPTION

[0029] In order to make the purpose and technical solution of the present invention clearer, the present invention is further described below in conjunction with embodiments, but the protection scope of the present invention is not limited to these embodiments, and the embodiments are only used to explain the present invention. It should be understood by those skilled in the art that any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention.

[0030] Example 1 Lenvatinib mesylate preparation (1000 tablets)

[0031] formula:

[0032]

[0033]

[0034] Preparation method:

[0035] (1) micronizing lenvatinib mesylate and rhusin to a D90 of 60 μm for later use;

[0036] (2) mixing the treated wild sumac glycoside with 1 / 2 weight part of dextrin and L-lactic acid, adding a wetting agent, wet granulating, drying, and granulating to obtain wild sumac glycoside granules;

[0037] (3) mixing the treated lenvatinib mesylate with the remaining dextrin and sodium bicarbonate, adding a wetting agent, wet granulating, drying, and granulating to obtain lenvatinib mesylate granules;

[0038] (4) Mix the wild sumac glycoside granules with the lenvatinib mesylate granules, add a disintegrant and a lubricant, and press into tablets to obtain the product.

[0039] Example 2 Lenvatinib mesylate preparation (1000 tablets)

[0040] formula:

[0041]

[0042] Preparation method:

[0043] (1) micronizing lenvatinib mesylate and rhusin to a D90 of 60 μm for later use;

[0044] (2) mixing the treated wild sumac glycoside with 1 / 2 weight part of dextrin and L-lactic acid, adding a wetting agent, wet granulating, drying, and granulating to obtain wild sumac glycoside granules;

[0045] (3) mixing the treated lenvatinib mesylate with the remaining dextrin and sodium bicarbonate, adding a wetting agent, wet granulating, drying, and granulating to obtain lenvatinib mesylate granules;

[0046] (4) Mix the wild sumac glycoside granules with the lenvatinib mesylate granules, add a disintegrant and a lubricant, and press into tablets to obtain the product.

[0047] Example 3 Lenvatinib mesylate preparation (1000 tablets)

[0048] formula:

[0049]

[0050] Preparation method:

[0051] (1) micronizing lenvatinib mesylate and rhusin to a D90 of 60 μm for later use;

[0052] (2) mixing the treated wild sumac glycoside with 1 / 4 weight portion of dextrin and L-lactic acid, adding a wetting agent, wet granulating, drying, and granulating to obtain wild sumac glycoside granules;

[0053] (3) mixing the treated lenvatinib mesylate with the remaining dextrin and sodium bicarbonate, adding a wetting agent, wet granulating, drying, and granulating to obtain lenvatinib mesylate granules;

[0054] (4) Mix the wild sumac glycoside granules with the lenvatinib mesylate granules, add a disintegrant and a lubricant, and press into tablets to obtain the product.

[0055] Example 4 Lenvatinib mesylate preparation (1000 tablets)

[0056] formula:

[0057]

[0058]

[0059] Preparation method:

[0060] (1) micronizing lenvatinib mesylate and rhusin to a D90 of 60 μm for later use;

[0061] (2) mixing the treated wild sumac glycoside with 3 / 4 parts by weight of dextrin and L-lactic acid, adding a wetting agent, wet granulating, drying, and granulating to obtain wild sumac glycoside granules;

[0062] (3) mixing the treated lenvatinib mesylate with the remaining dextrin and sodium bicarbonate, adding a wetting agent, wet granulating, drying, and granulating to obtain lenvatinib mesylate granules;

[0063] (4) Mix the wild sumac glycoside granules with the lenvatinib mesylate granules, add a disintegrant and a lubricant, and press into tablets to obtain the product.

[0064] Comparative Example 1 Lenvatinib mesylate preparation (1000 tablets)

[0065] formula:

[0066]

[0067] Preparation method:

[0068] (1) micronizing lenvatinib mesylate to a D90 of 60 μm for later use;

[0069] (2) mixing the treated lenvatinib mesylate with dextrin and sodium bicarbonate, adding a wetting agent, wet granulating, drying, and granulating to obtain lenvatinib mesylate granules;

[0070] (4) Mix the lenvatinib mesylate granules with a disintegrant and a lubricant, and press into tablets to obtain the product.

[0071] Comparative Example 2 Lenvatinib Mesylate Preparation (1000 Tablets)

[0072] formula:

[0073]

[0074] Preparation method:

[0075] (1) micronizing lenvatinib mesylate and rhusin to a D90 of 60 μm for later use;

[0076] (2) mixing the treated wild sumac glycoside with 1 / 2 weight part of dextrin and L-lactic acid, adding a wetting agent, wet granulating, drying, and granulating to obtain wild sumac glycoside granules;

[0077] (3) mixing the treated lenvatinib mesylate with the remaining dextrin, adding a wetting agent, wet granulating, drying, and granulating to obtain lenvatinib mesylate granules;

[0078] (4) Mix the wild sumac glycoside granules with the lenvatinib mesylate granules, add a disintegrant and a lubricant, and press into tablets to obtain the product.

[0079] Comparative Example 3 Lenvatinib mesylate preparation (1000 tablets)

[0080] formula:

[0081]

[0082] Preparation method:

[0083] (1) micronizing lenvatinib mesylate and rhusin to a D90 of 60 μm for later use;

[0084] (2) mixing the treated wild sumac glycoside with 1 / 2 weight portion of dextrin, adding a wetting agent, wet granulating, drying, and granulating to obtain wild sumac glycoside granules;

[0085] (3) mixing the treated lenvatinib mesylate with the remaining dextrin and sodium bicarbonate, adding a wetting agent, wet granulating, drying, and granulating to obtain lenvatinib mesylate granules;

[0086] (4) Mix the wild sumac glycoside granules with the lenvatinib mesylate granules, add a disintegrant and a lubricant, and press into tablets to obtain the product.

[0087] Comparative Example 4 Lenvatinib Mesylate Preparation (1000 Tablets)

[0088] formula:

[0089]

[0090] Preparation method:

[0091] (1) micronizing lenvatinib mesylate and rhusin to a D90 of 60 μm for later use;

[0092] (2) mixing the treated wild sumac glycoside, lenvatinib mesylate, dextrin, L-lactic acid, and sodium bicarbonate, adding a wetting agent, wet granulating, drying, and granulating to obtain granules A;

[0093] (3) Granule A is mixed with a disintegrant and a lubricant, and tabletted to obtain a tablet.

[0094] Comparative Example 5 Lenvatinib Mesylate Preparation (1000 Tablets)

[0095] formula:

[0096]

[0097]

[0098] Preparation method:

[0099] (1) micronizing lenvatinib mesylate and rhusin to a D90 of 60 μm for later use;

[0100] (2) mixing the treated wild sumac glycoside with 1 / 2 weight part of dextrin and L-lactic acid, adding a wetting agent, wet granulating, drying, and granulating to obtain wild sumac glycoside granules;

[0101] (3) mixing the treated lenvatinib mesylate with the remaining dextrin and sodium bicarbonate, adding a wetting agent, wet granulating, drying, and granulating to obtain lenvatinib mesylate granules;

[0102] (4) Mix the wild sumac glycoside granules with the lenvatinib mesylate granules, add a disintegrant and a lubricant, and press into tablets to obtain the product.

[0103] Comparative Example 6 Lenvatinib mesylate preparation (1000 tablets)

[0104] formula:

[0105]

[0106] Preparation method:

[0107] (1) micronizing lenvatinib mesylate and rhusin to a D90 of 60 μm for later use;

[0108] (2) mixing the treated wild sumac glycoside with 1 / 2 weight part of starch slurry and L-lactic acid, adding a wetting agent, wet granulating, drying, and granulating to obtain wild sumac glycoside granules;

[0109] (3) mixing the treated lenvatinib mesylate with the remaining starch slurry and sodium bicarbonate, adding a wetting agent, wet granulating, drying, and granulating to obtain lenvatinib mesylate granules;

[0110] (4) Mix the wild sumac glycoside granules with the lenvatinib mesylate granules, add a disintegrant and a lubricant, and press into tablets to obtain the product.

[0111] Pharmacodynamics experiments

[0112] 1. Experimental Animals

[0113] SD rats, SPF grade, 180-220 g, experimental animal license number: SYXK(Lu)20180008, were adaptively fed under standard conditions for 1 week before the experiment.

[0114] 2. Drugs and dosage

[0115] Example 1 Lenvatinib mesylate tablets: 0.9 mg / kg, calculated as lenvatinib mesylate;

[0116] Example 2 Lenvatinib mesylate tablets: 0.9 mg / kg, calculated as lenvatinib mesylate;

[0117] Comparative Example 1 Lenvatinib Mesylate Tablets: 0.9 mg / kg, calculated as Lenvatinib Mesylate;

[0118] Commercially available lenvatinib mesylate capsules (approval number H20180052): 0.9 mg / kg, calculated as lenvatinib mesylate;

[0119] 3. Modeling method and grouping

[0120] Subcutaneous tumor-bearing rats were killed by cervical dislocation, local disinfection was performed, and the subcutaneous tumor was removed. The tumor tissue with fish-like edges and no bleeding or necrosis was cut into 1 mm 3 The size of the tumor was prepared for implantation. Several SD rats were taken, anesthetized by intraperitoneal injection, and a midline incision was made in the upper abdomen after disinfection to expose the left lobe of the liver, puncture the liver capsule, make a 0.5-1cm tunnel under the capsule, implant the prepared tumor tissue block, and ensure that the tumor tissue did not withdraw and did not bleed, and immediately close the abdominal incision. The rats with successful modeling were taken to establish a model group, an embodiment 1 group, an embodiment 2 group, and a comparative example 1 group, with 10 rats in each group. The surgical operation of 10 rats in the blank group was basically the same as above, and no implantation treatment was performed.

[0121] 4. Drug administration

[0122] The rats in each treatment group were given corresponding drugs by gavage, and the rats in the blank group and model group were given an equal amount of normal saline by gavage, once a day, for 21 days.

[0123] 5. Statistical analysis

[0124] SPSS 22.0 software was used to analyze the data. The comparison among multiple groups was performed by one-way analysis of variance, and the comparison between two groups was performed by independent sample T test. P < 0.05 was considered statistically significant.

[0125] 6. Observation indicators and experimental results

[0126] 6.1 Tumor volume

[0127] Separate the tumor tissue and measure the maximum diameter of the tumor and the widest diameter perpendicular to the maximum diameter. Tumor volume = a × b 2 / 2, a is the maximum diameter of the tumor, and b is the widest diameter perpendicular to the maximum diameter.

[0128] Table 1 Rat tumor volume and tumor inhibition rate ( n=10)

[0129]

[0130] Note: Compared with the control group 1, *P<0.01.

[0131] 6.2HMGB1、VEGF

[0132] Figure 1 , 2 The expression levels of HMGB1 and VEGF in the tumor tissues of tumor-bearing rats in each group. The results showed that the expression of HMGB1 and VEGF in the tumor tissues of the tumor-bearing rats in the model group increased significantly. The expression of HMGB1 and VEGF in the tumor tissues of the administration groups decreased, and the expression of HMGB1 and VEGF in the tumor tissues of the rats in Example 1 and Example 2 groups decreased significantly, compared with the comparison example 1 group, P < 0.01, compared with the commercial group, P < 0.01, with significant differences.

[0133] In summary, the lenvatinib mesylate tablets of the present invention have excellent therapeutic effects on rats with liver cancer. The present invention combines wild lacquer glycoside with lenvatinib mesylate. Wild lacquer glycoside and lenvatinib mesylate act on liver cancer cells through different mechanisms, and can enhance the inhibitory effect on tumors under synergistic effects, thereby expanding the scope of indications for the treatment of liver cancer, especially for patients who do not respond well to traditional chemotherapy or single-drug targeted therapy.

[0134] Stability verification of lenvatinib mesylate preparation

[0135] The lenvatinib mesylate preparations of Examples 1 to 4 and Comparative Examples 2 to 6 were placed at 25° C. and 60% relative humidity for 12 months for a long-term test. The contents of lenvatinib mesylate and scutellaria baicalensis glycoside were determined on the first day, at the end of the second month, at the end of the sixth month, and at the end of the twelfth month during the experiment by high performance liquid chromatography.

[0136] The content of wild sumac glycosides was determined according to the high performance liquid chromatography method in the "Chinese Pharmacopoeia 2020 Edition".

[0137] Chromatographic conditions and system suitability test: octadecylsilane bonded silica gel is used as filler; methanol-0.5% phosphoric acid solution (43:57) is used as mobile phase; detection wavelength is 336nm. Preparation of reference solution: Take 10mg of wild sumac glycoside reference substance dried under reduced pressure with phosphorus pentoxide for 24 hours, accurately weigh, place in 100ml volumetric flasks, add 50% methanol to dissolve and dilute to scale, shake well; accurately measure 10ml of wild sumac glycoside reference solution, place in the same 50ml volumetric flask, add 50% methanol to dilute to scale, shake well, and obtain (each 1ml contains 20μg of wild sumac glycoside). Preparation of test solution: Take about 0.3g of the powder of this product (passed through No. 3 sieve), weigh accurately, place in a stoppered conical bottle, accurately add 50ml of 50% methanol, weigh, ultrasonically treat (power 250W, frequency 25kHz) for 1 hour, cool, weigh again, make up the lost weight with 50% methanol, shake well, filter, and take the filtrate to obtain. Determination method: Accurately take 10μl of the reference solution and the test solution respectively, inject into the liquid chromatograph, and determine to obtain.

[0138] Figure 3 is the change of lenvatinib mesylate content in long-term trials, Figure 4 The content of wild echinoside changes in long-term experiments. The experimental results of the embodiment and the comparative example show that lenvatinib mesylate and wild echinoside need to be treated separately, otherwise they will decompose. The lenvatinib mesylate preparation of the present invention solves this problem, while ensuring the efficacy, it improves the stability of the active ingredient.

[0139] Dissolution study

[0140] According to the second method (paddle method) of the dissolution test of the Chinese Pharmacopoeia 2020, the dissolution test of lenvatinib mesylate preparations prepared with different D90 particle sizes was performed. 900 ml of 0.1N (equivalent concentration) hydrochloric acid solution and pH 6.8 phosphate buffer + 0.3% sodium dodecyl sulfate (SDS) were used as the dissolution medium, respectively, and the dissolution test was carried out at 37±0.5°C and 50 rpm, and the dissolution was measured after 15 minutes of sampling.

[0141] Table 2D90 particle size and dissolution (%)

[0142] D90 Dissolution (%) 60μm 99.85 100μm 97.93 150μm 95.69 200μm 94.04

[0143] The results showed that the particle size of lenvatinib mesylate would affect its dissolution effect, and the dissolution was more complete when D90 was 60μm.

Claims

1. A lenvatinib mesylate preparation, characterized in that: The lenvatinib mesylate preparation is composed of the following ingredients: 2 to 15 parts by weight of lenvatinib mesylate, 1 to 7 parts by weight of wild sumac glycoside, 30 to 60 parts by weight of dextrin, 2 to 8 parts by weight of sodium bicarbonate, 0.5 to 3 parts by weight of L-lactic acid, 150 to 350 parts by weight of a filler, 4 to 25 parts by weight of a disintegrant, 0.5 to 5 parts by weight of a lubricant, and an appropriate amount of a wetting agent.

2. The lenvatinib mesylate preparation according to claim 1, characterized in that: The wetting agent is water and / or ethanol.

3. The lenvatinib mesylate preparation according to claim 1, characterized in that: The filler is selected from at least one of microcrystalline cellulose, mannitol, starch, sucrose and lactose.

4. The lenvatinib mesylate preparation according to claim 1, characterized in that: The disintegrant is selected from at least one of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, and cross-linked sodium carboxymethyl cellulose.

5. The lenvatinib mesylate preparation according to claim 1, characterized in that: The lubricant is selected from at least one of magnesium stearate, talcum powder, micro powder silica gel and polyethylene glycol.

6. The lenvatinib mesylate preparation according to claim 1 or 2, characterized in that: The wetting agent is an ethanol aqueous solution with a volume fraction of 15 to 35%.

7. A method for preparing the lenvatinib mesylate preparation according to claim 1, characterized in that: The method comprises the following steps: (1) micronizing lenvatinib mesylate and rhusin for later use; (2) mixing the treated wild sumac glycoside with 1 / 4 to 3 / 4 parts by weight of dextrin and L-lactic acid, adding a wetting agent, wet granulating, drying, and granulating to obtain wild sumac glycoside granules; (3) mixing the treated lenvatinib mesylate with the remaining dextrin and sodium bicarbonate, adding a wetting agent, wet granulating, drying, and granulating to obtain lenvatinib mesylate granules; (4) Mix the wild sumac glycoside granules with the lenvatinib mesylate granules, add a disintegrant and a lubricant, and press into tablets to obtain the product.

8. The method according to claim 7, characterized in that The amount of dextrin used in step (2) is 1 / 2 part by weight.

9. The method according to claim 7, characterized in that: The D90 of lenvatinib mesylate and rhusin after the micronization treatment is 60 μm.

10. Use of the lenvatinib mesylate preparation according to claim 1 in the preparation of anti-tumor drugs.

Citation Information

Cited By

  • Lovatinib mesylate capsule and preparation method thereof

    CN120837446A